Is there such a thing as ‘good’ and ‘bad’ drugs? From saving lives to creating addictive behaviours, this collection will reveal cutting edge discoveries and may change what you think you know about drugs.
More than 70% of deaths linked to drug use worldwide are related to opioids. How did these drugs designed to treat pain end up crippling communities? Read more
Dr Kelly E. Dunn
Dr Kelly E. Dunn has a multi-disciplinary training background that encompasses applied biopsychology, human behavioral pharmacology, and healthcare management. She began working in the field of opioid use disorder in 2005, when her graduate training allowed her to research optimal strategies for helping persons who were addicted to prescription opioids withdraw and abstain from opioids.
Since that point, she has worked on numerous randomized clinical trials that have evaluated different opioid and non-opioid medications, as well as behavioral interventions. Her recent work intertwines her training by focusing on understanding mechanisms of opioid effects and withdrawal symptoms and the complex interactions that exist between opioids, pain and other clinical outcomes, in order to develop effective, feasible and scalable strategies for helping patients.
Her research has been continually funded by the National Institutes of Health for the past decade, and includes rigorous human laboratory evaluations of opioid effects, randomized trials, comparisons of repurposed medications, and secondary outcomes from large epidemiological datasets to understand and forecast trends and treatment needs. She is strongly committed to advancing the care and well-being of persons affected by opioid use disorder.Read more